Lindsay Androski named CEO of Arbutus
Plus: CMO Maria Koehler steps down at Repare, and updates from Isomab, Crescent, Ottimo and Senti Bio
HBV therapies developer Arbutus Biopharma Corp. (NASDAQ:ABUS) has named Lindsay Androski CEO and replaced its entire board. Androski is special counsel at Genevant Sciences Corp., an RNA therapeutics company set up by Arbutus and Roivant Sciences Ltd. (NASDAQ:ROIV) in 2018 to advance treatments using Arbutus’ liquid nanoparticle and ligand conjugation technologies. She has held several roles at Roivant, including VP and head of acquisitions.
Michael McElhaugh, who had been Arbutus’ interim president and CEO since the start of 2024, has resigned from the board along with Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers and Melissa Rewolinski. The new board comprises Robert Beardsley, Anuj Hasija, Roivant CEO Matthew Gline, Roivant SVP of Finance Joseph Bishop, and Androski. Arbutus said the new team will review its development plans and strategic options for its HBV programs while “maximizing the company's contributions to LNP delivery technology through Genevant.”...